Liesegang T J
Department of Ophthalmology, Mayo Clinic Jacksonville, Florida, USA.
Cornea. 1998 Nov;17(6):574-83. doi: 10.1097/00003226-199811000-00001.
Enhance recognition by the external disease specialist of the conjunctival changes associated with glaucoma therapy and the reported association with glaucoma filtration surgery.
Literature search with emphasis on the cellular and subcellular changes induced by antiglaucoma medications, the definition and diagnosis of drug-induced cicatricial conjunctivitis (DICC), and the implications for future glaucoma therapy or surgery.
Significant conjunctival and subconjunctival changes occur associated with the use of antiglaucoma medications that affect the success of glaucoma filtration surgery. The extreme form of change is the DICC, which is clinically and pathologically identical to ocular cicatricial pemphigoid. The autoantigen in the basement membrane probably differs in these two disease processes.
There is a movement toward an earlier approach to glaucoma filtration surgery, in large part based on the literature reviewed here. The external disease specialist needs to be cognizant of these conjunctival changes to best consult on patients receiving antiglaucoma medications.
提高眼科疾病专科医生对与青光眼治疗相关的结膜变化以及所报道的与青光眼滤过手术相关性的认识。
进行文献检索，重点关注抗青光眼药物引起的细胞和亚细胞变化、药物性瘢痕性结膜炎（DICC）的定义和诊断，以及对未来青光眼治疗或手术的影响。
使用抗青光眼药物会出现显著的结膜和结膜下变化，这会影响青光眼滤过手术的成功率。变化的极端形式是DICC，其在临床和病理上与眼部瘢痕性类天疱疮相同。这两种疾病过程中基底膜中的自身抗原可能不同。
很大程度上基于此处综述的文献，目前有一种倾向于更早进行青光眼滤过手术的趋势。眼科疾病专科医生需要认识到这些结膜变化，以便为接受抗青光眼药物治疗的患者提供最佳咨询。
